Traditionally, CRISPR-based diagnostics such as SHERLOCK and DETECTR rely on RNA-guided Cas proteins, where target recognition is mediated through RNA surveillance complexes. However, the breakthrough with SLEUTH lies in decoupling target recognition from RNA guides by harnessing DNA-guided Cas12a effectors. This paradigm shift allows the system to gain robustness and versatility, overcoming inherent limitations associated with RNA guide instability and manufacturing challenges. DNA guides are notably more stable, easier to produce, and store, providing critical advantages for wide-scale diagnostic deployment in diverse settings ranging from benchtop laboratories to at-home testing kits.

The core workflow of the SLEUTH assay integrates isothermal amplification methods with DNA-guided Cas12a-mediated trans-cleavage of a fluorogenic reporter molecule, enabling a real-time readout of target presence. The process begins with the amplification of DNA or RNA targets through recombinase polymerase amplification (RPA) or reverse transcription RPA (RT-RPA), respectively. Following amplification, T7 transcription converts these DNA amplicons into RNA transcripts, which then activate the DNA-guided Cas12a. Upon activation, Cas12a executes collateral cleavage of a designed fluorescent reporter, generating measurable fluorescence signals that confirm the presence of target nucleic acids with exceptional sensitivity.

What marks SLEUTH’s diagnostic potential even more impressive is its demonstrated efficacy in distinguishing SARS-CoV-2 clinical samples with absolute accuracy within tested cohorts. In a study involving 31 patient samples, the platform delivered 100% concordance with standard quantitative PCR with reverse transcription (RT-qPCR), the current gold-standard diagnostic method for viral RNA detection. This congruence not only validates SLEUTH’s clinical reliability but also offers a quicker and potentially more scalable alternative for diagnosing viral infections in both clinical and remote environments.

A vital differentiator between SLEUTH and other CRISPR diagnostic platforms is the use of synthetic DNA guides rather than RNA components. This shift eradicates the necessity for engineered RNA in effector complexes, simplifying reagent formulations and reducing costs associated with synthesis and cold-chain logistics. In practical terms, this means that SLEUTH assays can be more readily manufactured at scale, stored for longer periods without significant degradation, and deployed in resource-limited settings without the stringent storage requirements that RNA-based reagents demand.

In essence, SLEUTH epitomizes a complementary diagnostic framework that augments—and in some aspects, surpasses—existing RNA-guided CRISPR systems. By integrating DNA-guided signal transduction with isothermal amplification, it circumvents some of the major technical challenges that have hampered broad CRISPR diagnostic rollout. Moreover, the system’s architecture allows for multiplexing and automation possibilities, offering a path toward portable, highly sensitive, and programmable nucleic acid testing devices in the near future.

Critically, the underlying technological innovation of the SLEUTH platform also opens new avenues for molecular diagnostics beyond viral detection. Because DNA-guided Cas12a effectors exhibit programmable RNA recognition and cleavage capabilities, this system can be engineered to target a vast landscape of RNA molecules, including genetic mutations, single nucleotide polymorphisms (SNPs), and other clinically relevant nucleic acid biomarkers. This versatility signals a shift toward precision diagnostics tailored for personalized medicine, where rapid and accurate profiling of molecular signatures is paramount.

Another advantage inherent to the SLEUTH platform is its adaptability to various nucleic acid targets through straightforward guide redesign. Unlike RNA-guided systems that require complex RNA synthesis and folding conditions, the DNA guides can be rapidly synthesized and modified, facilitating quick reconfiguration of the assay for new targets. This flexibility is especially useful in responding to emerging pathogens or evolving viral strains where speed is critical to diagnostic relevance and public health response.

The compatibility of SLEUTH with isothermal amplification chemistries such as RPA and RT-RPA further underscores its potential for field-deployable diagnostics. Isothermal methods eliminate the need for thermocyclers, minimizing equipment costs and simplifying assay execution. Leveraging this amplification with subsequent transcription and DNA-guided Cas12a detection creates a streamlined workflow that can be integrated into portable devices, point-of-care testing platforms, or even at-home diagnostic kits without sacrificing sensitivity or specificity.

Furthermore, the employment of a trans-cleavage-based fluorescent reporter readout facilitates real-time monitoring of nucleic acid amplification and detection events. This feature is pivotal for quantifying viral loads or biomarker concentrations dynamically, enhancing the diagnostic utility of the assay in clinical decision-making processes, treatment monitoring, and epidemiological surveillance.

Noteworthy is the conceptual distinction that, while inspired by SHERLOCK’s RNA-guided detection model, SLEUTH’s DNA-guided approach represents a fundamentally different mechanistic framework that broadens the CRISPR diagnostic landscape. By avoiding the intrinsic limitations of RNA guide handling and integrating a robust DNA-guided signaling mechanism, this platform introduces avenues for further engineering advances and integration with next-generation diagnostic technologies.

Researchers also stress that despite the dependence on nucleic acid amplification to achieve high sensitivity, such amplification remains a cornerstone for nearly all contemporary molecular diagnostics. The key innovation lies in how SLEUTH harmonizes amplification with DNA-guided Cas12a-mediated signal transduction, striking a balance between sensitivity, practicality, and reagent stability—a balance crucial for effective deployment during health crises.

Taken together, the development of the SLEUTH platform signifies a substantial leap forward in the field of CRISPR-enabled diagnostics. It not only dethrones the prevailing RNA-guide paradigm but does so by elevating diagnostic performance through synergistic biochemical design. As the research progresses toward broader clinical validation and commercialization, the potential impact of DNA-guided CRISPR systems extends far beyond infectious disease detection, signaling a new era in molecular precision diagnostics.

Given its outstanding attributes, SLEUTH is poised to play a pivotal role in future molecular testing infrastructures, empowering healthcare providers and individuals with rapid, sensitive, and stable nucleic acid testing capability. This advancement underscores the dynamic evolution of CRISPR technologies from genome editing tools to versatile diagnostic platforms, reshaping how we approach disease detection in the 21st century.

Subject of Research: DNA-guided CRISPR–Cas12a effectors for programmable RNA recognition and nucleic acid detection.

Article Title: DNA-guided CRISPR–Cas12a effectors for programmable RNA recognition and cleavage.

Article References:
Wu, X., Lam, W.H., Zhao, Z. et al. DNA-guided CRISPR–Cas12a effectors for programmable RNA recognition and cleavage. Nat Biotechnol (2026). https://doi.org/10.1038/s41587-026-03120-5

Image Credits: AI Generated

DOI: https://doi.org/10.1038/s41587-026-03120-5

CRISPR-Cas systems, originally discovered as adaptive immune defenses in bacteria, have rapidly evolved into versatile tools for genome editing and molecular detection. Cas12a, a member of the type V CRISPR family, is remarkable for both its programmable DNA-targeting ability and its collateral cleavage activity, in which after binding its specific target sequence, it non-specifically cleaves single-stranded DNA molecules nearby. This collateral or ‘trans-cleavage’ property has been harnessed in diagnostic platforms to amplify detection signals, transforming Cas12a into a powerful biosensing platform.

However, a persistent challenge limiting the sensitivity of Cas12a-based assays has been the balance between cis-cleavage (the direct cutting of the target DNA) and trans-cleavage (the collateral degradation used for signal amplification). Typically, the cis-cleavage occurs first, detaching the guide RNA-Cas12a complex from the target DNA, which can reduce collateral activity and thus diminish the overall signal strength. Addressing this kinetic bottleneck, the study led by Huang et al. presents a multi-guide RNA strategy that strategically biases Cas12a towards enhanced trans-cleavage, maximizing signal output and detection sensitivity.

The team designed an assay employing multiple guide RNAs, each targeting distinct sites on the pathogen DNA. This multiplex approach ensures sustained activation of Cas12a’s trans-cleavage function by providing repeated target engagement opportunities. By simultaneously engaging multiple genomic loci, the system maintains Cas12a in an activated state longer, overcoming the transient nature of single-guide interactions. The outcome is a significant amplification of the collateral cleavage signal, enabling the detection of extremely low abundance DNA molecules that would otherwise evade conventional assays.

Underlying this method is a sophisticated understanding of Cas12a enzymology and kinetics. The researchers carefully examined how guide RNA multiplicity alters Cas12a’s cleavage dynamics. Their data revealed that multi-guide RNA loading not only increased the enzyme’s dwell time on target DNA but also created a kinetic environment favoring robust trans-cleavage over cis-cleavage. This mechanistic insight underpins the assay’s dramatic sensitivity improvements, which could have broad implications for pathogen detection in clinical and environmental samples.

Moreover, the assay design incorporates strategic bioinformatics to select guide RNAs that minimize off-target effects while maximizing coverage of pathogen genomes. This ensures high specificity, critical for avoiding false positives in complex sample backgrounds. The ability to distinguish closely related DNA sequences with exceptional accuracy positions this multi-guide RNA Cas12a assay as a superior alternative to existing PCR and isothermal amplification techniques, which often suffer from primer-dimer artifacts and lower multiplexing capacity.

Experimental validation was conducted using a diverse panel of infectious agents, demonstrating that the assay not only detects target DNA at femtomolar concentrations but does so with remarkable reproducibility and speed. The reaction completes within minutes under isothermal conditions, making it well-suited for point-of-care diagnostics where rapid decision-making is crucial. Importantly, the streamlined workflow requires minimal sample processing and standard laboratory equipment, lowering the barrier for widespread implementation.

A particularly compelling aspect of this development is its adaptability. The modular nature of guide RNA design allows swift reconfiguration of the assay to monitor emerging pathogens or detect mutations conferring drug resistance. As infectious disease landscapes evolve, the capacity to quickly deploy ultra-sensitive diagnostic tools will be instrumental in outbreak containment and patient treatment optimization.

Additionally, the improved signal-to-noise ratio from enhanced trans-cleavage translates to the potential for simple readout systems, including fluorescent or colorimetric outputs that can be visualized without complex instrumentation. This feature paves the way for affordable, user-friendly diagnostics accessible in resource-limited settings, bridging gaps in global health surveillance and response.

Beyond infectious diseases, the principles elucidated with this multi-guide RNA Cas12a assay open avenues for detecting genetic biomarkers relevant to cancer, genetic disorders, and environmental monitoring. The platform’s intrinsic versatility underscores the broad utility of CRISPR-based diagnostics as a transformative technology across biomedical disciplines.

The inclusion of real-time monitoring to track cleavage kinetics further advances our mechanistic understanding, enabling refinement of guide RNA combinations and reaction conditions for tailored applications. This precision engineering harnesses the full enzymatic potential of Cas12a, pushing the boundaries of sensitivity and specificity in nucleic acid detection.

Overall, the novel multi-guide RNA Cas12a assay capitalizes on molecular synergies that amplify detection capabilities far beyond current standards. Huang and colleagues’ work exemplifies the intersection of molecular biology, bioengineering, and diagnostic innovation, setting a new benchmark for pathogen DNA sensing that promises to accelerate both research and clinical workflows.

As CRISPR-based tools continue to mature, this study highlights the untapped potential within Cas enzyme kinetics that can be manipulated to create next-generation diagnostics. The focus on tuning cleavage activity—particularly favoring trans- versus cis-cleavage—represents a paradigm shift in how these enzymes can be deployed for molecular detection.

Looking forward, integrating this assay with microfluidic platforms and automated sample handling could yield fully integrated, portable diagnostic devices slashing turnaround times from hours to minutes. Such technology would be especially impactful during emerging global health emergencies requiring rapid, decentralized testing solutions.

Furthermore, combining this multi-guide RNA Cas12a system with other CRISPR effectors or amplification strategies could enhance multiplexing and allow simultaneous detection of multiple pathogens or genetic variants within a single test—a powerful capability to navigate complex diagnostic landscapes.

The study’s findings also prompt deeper exploration into CRISPR dynamics, encouraging researchers to exploit other enzymes’ cleavage properties strategically. This could inspire a wider suite of highly sensitive and programmable molecular diagnostic assays tailored to diverse clinical and environmental needs.

In conclusion, the multi-guide RNA Cas12a assay introducing a preferential trans-cleavage activation mechanism is a landmark advancement in nucleic acid detection technology. By elegantly engineering guide RNA arrays to harness Cas12a’s collateral cleavage potential fully, Huang and colleagues have unlocked powerful new diagnostic possibilities destined to reshape infectious disease detection, molecular medicine, and beyond.

Subject of Research: Sensitive detection of pathogen DNA using a novel CRISPR-Cas12a-based assay with multi-guide RNAs designed to favor trans-cleavage over cis-cleavage activity for enhanced sensitivity.

Article Title: Sensitive pathogen DNA detection by a multi-guide RNA Cas12a assay favoring trans- versus cis-cleavage.

Article References:
Huang, Z., Song, Z., Zeng, J. et al. Sensitive pathogen DNA detection by a multi-guide RNA Cas12a assay favoring trans- versus cis-cleavage. Nat Commun 16, 8257 (2025). https://doi.org/10.1038/s41467-025-63094-x

Image Credits: AI Generated

The President-Elect, Dr. Yassmine M.N. Akkari, brings expertise from Nationwide Children’s Hospital and The Ohio State University College of Medicine, where her work integrates molecular techniques with clinical applications aimed at enhancing diagnostic precision. This strategic choice reflects AMP’s emphasis on bridging translational science and patient care, a hallmark of molecular pathology that drives personalized medicine forward. Dr. Akkari’s leadership is expected to elevate the society’s impact on fostering interdisciplinary molecular diagnostic approaches.

In parallel, the appointment of Dr. Jonathan A. Nowak as Secretary-Treasurer further strengthens AMP’s governance. Dr. Nowak’s base at Brigham and Women’s Hospital and Harvard Medical School situates him within one of the most prestigious research hubs for molecular pathology. His dual M.D. and Ph.D. backgrounds position him uniquely to steward AMP’s resources while promoting rigorous scientific standards vital for the rapid evolution of diagnostic paradigms.

The Program Committee Chair-Elect, Dr. Rena R. Xian from Johns Hopkins University School of Medicine, will oversee the critical task of curating AMP’s educational offerings and scientific discourse. In an era where molecular diagnostic technologies evolve at a breakneck pace, her role is essential in ensuring that AMP’s programs not only reflect the latest research but also anticipate future directions in molecular pathology, bioinformatics, and precision oncology.

AMP’s various subdivisions, each representing specialized areas within molecular pathology, underscore the breadth and depth of the society’s expertise. The Genetics Subdivision, for instance, plays a pivotal role in elucidating the molecular underpinnings of hereditary diseases and cancer predisposition. Leaders such as Dr. Panieh Terraf from Memorial Sloan Kettering Cancer Center and Dr. Jennifer Laffin of the University of Minnesota Twin Cities reflect a robust commitment to advancing genetic diagnostics, integrating cutting-edge genomic technologies into clinical practice.

Within the Hematopathology Subdivision, the appointments—including Chair Mark D. Ewalt and clinical representatives like Dr. Kevin E. Fisher—highlight ongoing efforts to refine molecular diagnostic criteria for hematologic malignancies. These leaders represent institutions common to transformative research in hematology, emphasizing molecular mechanisms, biomarker identification, and therapeutic stratification essential for disease management.

The Infectious Diseases Subdivision also gains renewed leadership, with experts such as Dr. Heather Glasgow from St. Jude Children’s Research Hospital contributing to AMP’s mission. Molecular diagnostics in infectious diseases are experiencing unprecedented growth, fueled by rapid pathogen detection methods and genomic epidemiology. AMP’s leadership ensures these advances are translated into standards and educational initiatives that bolster diagnostic accuracy and outbreak preparedness.

Informatics, a critical frontier in molecular diagnostics, is represented by leaders like Dr. Jeffrey Gagan of the National Institutes of Health. The integration of computational biology, bioinformatics, and data science within AMP reflects the increasing reliance on algorithms and machine learning for interpreting complex genomic data sets. This subdivision’s stewardship is crucial as the society navigates the challenges and opportunities presented by big data in molecular pathology.

The Solid Tumors Subdivision, led by Chair Dr. Jaclyn F. Hechtman, underscores the vital role that molecular pathology plays in oncology. With the expansion of targeted therapies and precision medicine, AMP’s leadership insists on advancing diagnostic frameworks that identify actionable mutations and resistance mechanisms, ensuring patient-specific therapeutic interventions. The presence of representatives from leading cancer centers confirms AMP’s dedication to bridging research and clinical application.

Beyond individual roles, AMP’s leadership structure embodies a collaborative framework designed to foster interdisciplinary scholarship and education. The newly elected committee chairs and representatives are tasked with advancing training programs and publications, ensuring that molecular pathology professionals remain equipped with current knowledge and innovative diagnostic tools. This approach aligns with AMP’s foundational goal: to provide leadership that cultivates progress in molecular diagnostics.

AMP’s influence extends beyond its membership. With over 3,100 members worldwide, including pathologists, scientists, and technologists, the society actively shapes the standards of molecular diagnostics across academic, clinical, government, and industry settings. The new leadership is poised to continue this trajectory, facilitating global dialogue and promoting scientific advancements that improve patient outcomes.

Reflecting on AMP’s history since its inception in 1995, the organization has evolved amid an era of extraordinary scientific development. Molecular diagnostics have transitioned from niche research to standard clinical practice, revolutionizing disease detection, prognosis, and treatment monitoring. AMP’s leadership elections symbolize the society’s ongoing commitment to guiding this evolution through expertise, innovation, and education.

In conclusion, the announcement of AMP’s 2026–2027 leadership representatives not only signifies a renewal of stewardship but also heralds an era poised for scientific breakthroughs in molecular pathology. These leaders represent the dynamism and innovation critical for advancing molecular diagnostics, thus ensuring that AMP remains at the vanguard of this transformative field.

Subject of Research: Molecular diagnostics and leadership in molecular pathology professional society
Article Title: Association for Molecular Pathology Announces 2026–2027 Leadership Election Results
News Publication Date: June 23, 2025
Web References: http://www.amp.org
Keywords: Molecular diagnostics, molecular pathology, genetics, hematopathology, infectious diseases, bioinformatics, oncology, precision medicine, professional society, clinical practice, education, leadership

In an innovative exploration published recently, scientists have unveiled an ultrasensitive detection method centered on a newly discovered circular RNA (circRNA) biomarker named hsa_circ_0049101. CircRNAs are a unique class of RNA molecules characterized by their covalently closed loop structures, which provide greater stability than linear RNAs, making them promising candidates for cancer biomarkers. This study identifies hsa_circ_0049101 in ovarian cancer patients, heralding a new frontier in molecular diagnostics by offering enhanced specificity to ovarian malignancies.

The detection strategy hinges on integrating reverse transcription rolling circle amplification (RT-RCA) with CRISPR-Cas12a system, a cutting-edge gene-editing tool repurposed here for molecular diagnostics. RT-RCA serves to exponentially amplify the target circRNA, converting it into abundant DNA concatemers which then become substrates for Cas12a-mediated detection. The marriage of these two powerful technologies enables a synergistic enhancement in sensitivity, surpassing conventional detection thresholds.

What truly distinguishes this approach is the application of a dual Cas12a system, employing two distinct Cas12a orthologs, FnCas12a and LbCas12a, alongside a multiplexed CRISPR RNA (crRNA) array. This combination, referred to as the DCMC-CRISPR (Dual Cas12a and Multiplex crRNA CRISPR) platform, amplifies the detection signal through simultaneous targeting by multiple crRNAs and the complementary activities of two Cas12a nucleases. This multifaceted targeting ensures a robust, sensitive, and specific response to even trace levels of the circRNA biomarker.

Detailed mechanistic studies elucidate that multiplex crRNAs recognize discrete regions on the rolling circle amplified product, thereby maximizing Cas12a activation. This leads to an enhanced collateral cleavage activity, dramatically increasing the fluorescent or colorimetric readout signal which forms the basis for detection. Notably, this method achieves a limit of detection as low as 0.5 femtomolar, demonstrating remarkable ultrasensitivity that is 4 to 11 times superior to traditional single-crRNA Cas12a assays.

The dynamic detection range spans from nanomolar to femtomolar concentrations, covering a wide spectrum vital for clinical relevance. This expansive range ensures that the assay can sensitively detect early-stage, low abundance biomarker molecules as well as elevated levels found in advanced disease, presenting a versatile tool adaptable to various diagnostic scenarios.

Clinical validation of the DCMC-CRISPR assay involved analysis of RNA extracts derived from peripheral blood samples of ovarian cancer patients compared against healthy controls. The results showcased the assay’s superior diagnostic performance relative to the established serum biomarkers, CA-125 and HE4, as well as the ROMA index, which is a commonly used risk assessment tool combining these markers. The DCMC-CRISPR method demonstrated both higher sensitivity and specificity, suggesting its potential to reduce false positives and missed diagnoses inherent to current clinical assays.

Furthermore, this assay showed diagnostic accuracy comparable to real-time quantitative PCR (RT-qPCR), the current gold standard in nucleic acid detection, while providing benefits in ease of use, lower resource requirements, and faster turnaround times. The amalgamation of isothermal amplification with CRISPR detection can potentially enable point-of-care testing, facilitating earlier intervention and better patient outcomes.

From a technical perspective, the use of RT-RCA to convert circRNA targets into concatemerized DNA sequences is ingenious, as it not only amplifies the target but also converts a challenging RNA molecule into a DNA form amenable to CRISPR targeting. The choice and engineering of two Cas12a orthologs exploit their differing PAM preferences and enzymatic kinetics, broadening targeting scope and catalytic efficiency.

The multiplex crRNA design is another remarkable facet, as it leverages the inherent programmability of CRISPR to design multiple guide RNAs that can simultaneously bind different target sites on the amplified DNA, effectively multiplying the cleavage events. This innovation addresses the common challenge of limited sensitivity seen with single guide RNA systems, particularly for low abundance targets.

Beyond ovarian cancer, the implications of this platform are profound. CircRNAs are emerging as biomarkers across various cancers and diseases, reflecting underlying pathophysiological states. The modularity of the DCMC-CRISPR platform allows for facile reprogramming of crRNAs to detect different circRNA sequences, making it a potentially universal tool for biomarker discovery and clinical diagnostics across oncology and beyond.

The study also opens doors for integrating this technology with portable and automated devices, creating opportunities for decentralized screening programs and personalized medicine. By drastically lowering detection limits and increasing assay reliability, this method could revolutionize early cancer detection and monitoring, particularly in resource-limited settings where conventional molecular diagnostics are inaccessible.

Despite these advances, further large-scale clinical validation is necessary to fully ascertain the assay’s performance across diverse patient populations and cancer subtypes. Additionally, integration into clinical workflows will require addressing regulatory and manufacturing challenges to ensure robustness, reproducibility, and cost-effectiveness.

In summary, this pioneering research underscores the transformative potential of combining advanced nucleic acid amplification techniques with multiplexed CRISPR detection. The discovery of hsa_circ_0049101 as a novel ovarian cancer biomarker, coupled with the innovative DCMC-CRISPR platform, represents a significant leap forward in non-invasive, ultrasensitive cancer diagnostics. This work exemplifies the forefront of molecular medicine, where precision tools intersect with novel biology to tackle one of the most daunting cancers.

As research progresses, this integrated detection strategy could contribute significantly to shifting ovarian cancer from a disease often caught too late to one detected in its earliest and most treatable stages. It holds promise not only for improving survival rates but also for paving the way toward personalized and preventive oncology.

—

Subject of Research: Ovarian cancer diagnosis using ultrasensitive detection methods based on novel circRNA biomarkers and CRISPR-Cas12a technology.

Article Title: Dual Cas12a and multiplex crRNA CRISPR strategy ultrasensitive detection novel circRNA biomarker for the diagnosis of ovarian cancer.

Article References:
Tian, L., Gao, Y., Zi, L. et al. Dual Cas12a and multiplex crRNA CRISPR strategy ultrasensitive detection novel circRNA biomarker for the diagnosis of ovarian cancer.
BMC Cancer 25, 695 (2025). https://doi.org/10.1186/s12885-025-14116-w

Image Credits: Scienmag.com

DOI: https://doi.org/10.1186/s12885-025-14116-w